Dossier assessment
Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with moderately to severely active Crohn’s disease
- Adults who have had an inadequate response, lost response or were intolerant to conventional therapy: added benefit not proven
- Adults who have had an inadequate response, lost response or were intolerant to a biologic agent (tumour necrosis factor alpha antagonist or integrin inhibitor or interleukin inhibitor): added benefit not proven
Press releases
Upadacitinib in active Crohn’s disease: no added benefit proven due to lack of comparative studies
Project details
- Project no.
- A23-38
- Commission
- Commission awarded on 28.04.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Upadacitinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Upadacitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Upadacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Upadacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Upadacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Upadacitinib (giant cell arteritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed